Summary of Significant Accounting Policies (Tables)

9 Months Ended

Dec. 31, 2018

Summary Of Significant Accounting Policies Tables

Summary of stock-based compensation expense

	Three Months Ended December 31,				Nine Months Ended December 31,
	2018		2017		2018		2017
Research and development expense:
Stock option grants	$	274,900	$	299,100	$	955,600	$	627,400
General and administrative expense:
Stock option grants		459,800		390,200		1,564,100		759,500
Total stock-based compensation expense	$	734,700	$	689,300	$	2,519,700	$	1,386,900

Fair value assumptions

Assumption:	August 2018
Market price per share at grant date	$	1.27
Exercise price per share	$	1.27
Risk-free interest rate		2.84	%
Expected term in years		5.50
Volatility		99.29	%
Dividend rate		0.0	%
Shares		860,000
Fair Value per share	$	0.98

Assumption:	Pre-modification			Post-modification
Market price per share	$	1.49		$	1.49
Exercise price per share	$	3.57		$	1.50
Risk-free interest rate		2.77	%		2.77	%
Remaining expected term in years		5.08			5.08
Volatility		94.9	%		94.9	%
Dividend rate		0.0	%		0.0	%
Number of option shares		2,419,503			2,419,503
Weighted average fair value per share	$	0.91		$	1.08

Assumption:	October 2018
Market price per share at grant date	$	1.83
Exercise price per share	$	1.83
Risk-free interest rate		3.13	%
Expected term in years		10.00
Volatility		89.98	%
Dividend rate		0.0	%
Shares		250,000
Fair Value per share	$	1.59

Schedule of potentially dilutive securities excluded from computation of earnings per share

	As of December 31,
	2018		2017
Series A Preferred stock issued and outstanding (1)		750,000		750,000
Series B Preferred stock issued and outstanding (2)		1,160,240		1,160,240
Series C Preferred stock issued and outstanding (3)		2,318,012		2,318,012
Outstanding options under the Amended and Restated 2016 (formerly 2008) and 1999 Stock Incentive Plans (1999 Plan in 2017 only)		6,410,338		3,279,871
Outstanding warrants to purchase common stock		21,499,955		16,918,292
Total		32,138,545		24,426,415